TITLE

Gut and mind

AUTHOR(S)
Neary, N.M.; Small, C.J.; Bloom, S.R.
PUB. DATE
July 2003
SOURCE
Gut;Jul2003, Vol. 52 Issue 7, p918
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Obesity is a growing epidemic, causally associated with a number of serious medical conditions, including diabetes mellitus, coronary heart disease, and several cancers. The gut hormones ghrelin and peptide YY are secreted from the gut in response to changes to nutritional status. While food intake is stimulated by ghrelin, it is inhibited by peptide YY. The discovery, anatomy, and physiology of ghrelin and peptide YY are discussed, focusing on the adaptive changes in diseases such as obesity and anorexia nervosa. Ghrelin and PYY are important therapeutic targets in the quest to find an effective antiobesity treatment.
ACCESSION #
10998091

 

Related Articles

  • Increased Carbohydrate Induced Ghrelin Secretion in Obese vs. Normal-weight Adolescent Girls. Misra, Madhusmita; Tsai, Patrika M.; Mendes, Nara; Miller, Karen K.; Klibanski, Anne // Obesity (19307381);Sep2009, Vol. 17 Issue 9, p1689 

    Orexigenic and anorexigenic pathways mediate food intake and may be affected by meal composition. Our objective was to determine whether changes in levels of active ghrelin and peptide YY (PYY) differ in obese vs. normal-weight adolescent girls following specific macronutrient intake and predict...

  • GHRELIN: A NEW PLAYER IN THE CONTROL OF GASTROINTESTINAL FUNCTIONS. Peeters, T. L. // Gut;Nov2005, Vol. 54 Issue 11, p1638 

    Ghrelin is the endogenous ligand for the growth hormone secretagogue receptor (GHS-R), present on pituitary cells secreting growth hormone. Ghrelin and motilin, and GHS-R and the motilin receptor, are structurally related. Surprisingly, ghrelin is most abundant in the stomach, and GHS-R is also...

  • Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Kobelt, P.; Helmling, S.; Stengel, A.; Wlotzka, B.; Andresen, V.; Klapp, B. F.; Wiedenmann, B.; Klussmann, S.; Mönnikes, H. // Gut;Jun2006, Vol. 55 Issue 6, p788 

    Background and aims: Ghrelin, the natural ligand of the growth hormone secretagogue receptor 1 a, is the most powerful peripherally active orexigenic agent known. In rodents, ghrelin administration stimulates growth hormone release, food intake, and adiposity. Because of these effects, blocking...

  • Bariatric surgery induces weight loss primarily by mechanical restriction and nutrient malabsorption. KAPLAN, LEE M.; SEELEY, RANDY J.; HARRIS, JASON L. // Bariatric Times;Apr2014, Vol. 11 Issue 4, pc8 

    The article discusses the role of bariatric surgery for the prevention of obesity. Topics discussed include the mechanisms of bariatric surgery, the impacts of bariatric surgery on patient health and the physiological effects of the Roux-en-Y gastric bypass surgery. It also discusses the role of...

  • Gut hormone to fight obesity.  // GP: General Practitioner;1/19/2007, p4 

    The article presents information on a research related to the use of gut hormone, pancreatic polypeptide to reduce obesity. It is observed that pancreatic polypeptide could form the basis of a drug to tackle obesity since it reduces the number of adipocyte cells. It is stated that adipocyte...

  • Narrative Review: Effect of Bariatric Surgery on Type 2 Diabetes Mellitus. Vetter, Marion L.; Cardillo, Serena; Rickels, Michael R.; Iqbal, Nayyar // Annals of Internal Medicine;1/20/2009, Vol. 150 Issue 2, p94 

    Bariatric surgery leads to substantial and durable weight reduction. Nearly 30% of patients who undergo bariatric surgery have type 2 diabetes, and for many of them, diabetes resolves after surgery (84% to 98% for bypass procedures and 48% to 68% for restrictive procedures). Glycemic control...

  • Comparative Effects of the Long-Acting GLP-1 Receptor Ligands, Liraglutide and Exendin-4, on Food Intake and Body Weight Suppression in Rats. Hayes, Matthew R.; Kanoski, Scott E.; Alhadeff, Amber L.; Grill, Harvey J. // Obesity (19307381);Jul2011, Vol. 19 Issue 7, p1342 

    The glucagon-like-peptide-1 receptor (GLP-1R) agonists, liraglutide (Victoza) and the synthetic product of exendin-4 (Byetta), are approved for type II diabetes mellitus (T2DM) treatment and may be efficacious in obesity treatment as well, in part, due to the drugs' resistance to enzymatic...

  • Changes in neurohormonal gut peptides following bariatric surgery. Ochner, C. N.; Gibson, C.; Shanik, M.; Goel, V.; Geliebter, A. // International Journal of Obesity;Feb2011, Vol. 35 Issue 2, p153 

    The rising prevalence of obesity has reached pandemic proportions, with an associated cost estimated at up to 7% of health expenditures worldwide. Bariatric surgery is currently the only effective long-term treatment for obesity and obesity-related co-morbidities in clinically severely obese...

  • A rat model of childhood diet-induced obesity: Roux-en-Y gastric bypass induced changes in metabolic parameters and gastric peptide ghrelin. Aprahamian, Charles; Tekant, Gonça; Chen, Min; Yagmurlu, Ayden; Yang, Ying-kui; Loux, Tara; Harmon, Carroll // Pediatric Surgery International;Jul2007, Vol. 23 Issue 7, p653 

    Childhood morbid obesity is reaching epidemic proportions. Roux-en-Y gastric bypass (RYGB) results in many metabolic alterations, including changes in glucose and lipid metabolism, and changes in levels of the gastric hormone, ghrelin. As more children are undergoing RYGB, an animal model would...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics